Biotech and the San Antonio economy by Keith R. Phillips & Maria Ritka Dzula
Biotechnology is the boat no
one wants to miss. Biotech has be-
come the buzzword for new eco-
nomic development, much the way
high tech was in the 1990s. Cities
and states are looking to biotech
for new jobs and tax revenues.
And though the total percentage
of biotech employment is cur-
rently small, the industry’s growth
potential and its high-wage jobs
hold much promise.
While investors have recently
grown cautious, many areas are
increasingly seeking to establish
themselves as biotech beacons
and re-create the success of indus-
try clusters like those in Boston
and San Francisco. San Antonio is
no exception. 
Biotechnology Defined 
In the mid-1980s the congres-
sional Office of Technology Assess-
ment defined biotechnology as
“any technique that uses living
organisms or substances from those
organisms, to make or modify a
product, to improve plants or ani-
mals, or to develop microorgan-
isms for specific uses.” Delineating
the biotech industry’s parameters
is less easy, and many different
definitions are used. We focus on
the two most common. 
A study by accounting firm
Ernst & Young defines biotech
narrowly, limiting the industry to
pharmaceuticals and research. A
more recent study by the Texas
Healthcare & Bioscience Institute
uses a broader definition that also
includes medical devices (Table 1).
Biotech in San Antonio
San Antonio is home to many
successful biotech companies. For
example, ILEX Oncology Inc., a
pharmaceutical and research labo-
ratory, is a leading developer of
cancer drugs. The May 2001 issue
of  Technology Review ranks Bio-
Numerick Pharmaceuticals 16th
among U.S. biotech firms in terms
of the quantity and quality of its
patents. Other important biotech
players in San Antonio are Brooke
Army Medical Center, the Univer-
sity of Texas Health Science Center,
Institute for Drug Development,
Texas Research Park Foundation,
Southwest Research Institute, South-
west Foundation for Biomedical
Research, and Cancer Therapy &
Research Center.
A 2002 report from the Brook-
ings Institution Center on Urban
and Metropolitan Policy divides the
51 largest U.S. metropolitan areas
into four general groups: biotech-
nology centers, research centers,
median metropolitan areas, and no
significant biotech research or com-
mercialization.
1 The biotech centers
are the consolidated metropolitan





Spring 2003 South Texas











much promise.San Francisco, San Diego, Seattle,
New York, Philadelphia, Los
Angeles and Washington and the
metropolitan statistical area (MSA)
of  Raleigh–Durham. These nine
areas have above-average shares
of total U.S. biotech research
activity and commercialization,
based on National Institutes of
Health funding, patents, research,
venture capital in biopharmaceu-
ticals, value of biotech research
alliances, new biotech firms, large
biotech firms and an index of
biotech commercialization.
The San Antonio MSA is one
of 28 areas categorized as a me-
dian metropolitan area because
it has a biotechnology presence,
but at levels well below the aver-
age of the 51 areas in the sample.
Dallas–Fort Worth and Austin–San
Marcos fall into the same cate-
gory, while Houston is one of
four cities classified as a research
center, defined as above-average
research activity but below-aver-
age commercialization.
Because the Brookings report
looks at how the industry is dis-
persed across the country, larger
metro areas are more likely to be
classified as biotech centers sim-
ply because of their size. Alter-
natively, we can look at biotech
as a share of the metro area’s
industries or jobs. As of fourth
quarter 2000, San Antonio’s bio-
tech sector was 0.6 percent of
total employment (3,908 biotech
jobs) using the narrow definition
from Table 1 and 1 percent (6,574
jobs) of total employment using
the broader definition.
While biotech represents a
small share of jobs in San Antonio
Table 1
Two Ways to Look at Biotech
Ernst & Young Industry
Pharmaceuticals SIC Code
2833 Medicinal Chemicals and 
Botanical Products
2834 Pharmaceutical Preparations
2835 In Vitro and In Vivo Diagnostic Substances
2936 Biological Products, 
Except Diagnostic Substances
Laboratories and Research
8731 Commercial Physical and 
Biological Research
Texas Healthcare & Bioscience Institute
also includes:
Medical Devices  SIC Code
3841 Surgical and Medical Instruments
3842 Orthopedic, Prosthetic, and 
Surgical Appliances and Supplies
3843 Dental Equipment and Supplies





SOURCES: Ernst & Young, The Economic Contributions of the Biotechnology Industry to the 
U.S. Economy, report for Biotechnology Industry Organization, May 2000;
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Vista • Spring 2003 2tech—relatively weak growth in
Austin biotech jobs and strong
growth in San Antonio biotech
jobs. During this period, biotech
jobs in Austin declined 15.9 per-
cent using the narrow definition
and increased a moderate 4.1
percent using the broad defini-
tion. In contrast, in San Antonio
the narrowly defined biotech in-
dustry grew by 19.5 percent and
the broadly defined industry by
26.6 percent.  
The data in Chart 1 are based
on the Standard Industrial Clas-
sification (SIC) system, which the
Bureau of Labor Statistics used
until the end of 2000. Beginning
in 2001, the employment data
presented in the charts were
reclassified using the North
American  Industry Classification
System (NAICS). NAICS  was first
and other Texas cities, it could
be a significant source of growth,
and it is a high-wage sector. In
2000, average annual biotech
wages in San Antonio were
$51,200 (narrow definition) and
$48,702 (broad definition). These
wages are well above the 2000
overall local average of $29,549
and the state average of $34,943.
2
As Chart 1 shows, San Antonio
has maintained a steady share of
biotech jobs, meaning they have
generally grown at the same rate
as the average of all other indus-
tries. And while this share is small
by both definitions, it is second
only to Austin’s among the state’s
large metro areas. During the
1990s the gap between Austin
and San Antonio declined due to
the rapid increase in nonbiotech
industries in Austin—mainly high
San Antonio’s 
share of biotech 
jobs is second 
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SOURCE: Texas Workforce Commission.
NOTE: For definitions, see Table 1.biotech research centers or Texas
median biotech metro areas, San
Antonio ranks seventh in the share
of jobs in biotech R&D (Chart 2).
And while San Antonio ranks a
much lower 11th in the share of
pharmaceutical jobs, a disaggre-
gated version of the SIC data in
Chart 1 shows that pharmaceuti-
cal jobs grew 54 percent from
1997 to 2000. Thus the 1997 Eco-
nomic Census, which allows a
comparison of biotech jobs across
metro areas, shows a relatively
strong biotech R&D presence in
San Antonio but a weakness in
pharmaceuticals. More recent data,
however, suggest strong pharma-
ceuticals growth since 1997. 
Another important measure
of the biotech industry is the
number of patents granted. Patent
creation marks a biotech com-
pany’s maturation and is key to
raising capital for new research
and development. The number
of patents generated in San
Antonio sheds light on how local
biotech companies are using
their intellectual capital and on
the companies’ growth potential.
The U.S. Patent and Trade-
mark Office uses the term inven-
tor city to refer to where the
inventor lives when a patent is
issued. Assignee city refers to the
location of the party that owns
the patent. In terms of inventor
city, the patent office granted
Texas 2,828 biotech-related pat-
ents between 1996 and 2002. Of
them, 66 percent went to the four
top metro areas: 791 to Houston,
488 to Dallas–Fort Worth, 366 to
San Antonio and 218 to Austin.
3
San Antonio appears to be
competitive in patents issued by
inventor city, especially in rela-
tion to its size. In patents per
capita, San Antonio ranks first
(0.0233 percent), Austin second
(0.0181 percent), Houston third
(0.0172 percent) and Dallas–Fort
Worth fourth (0.00953 percent).
However, when biotech patents
are viewed in terms of assignee
city, the rankings change. Austin
is the leader with 620 assignee
patents, followed by Houston with
373, Dallas with 318 and San
Antonio with 184. Adjusting for
population size, Austin is far
used, however, in the 1997
Economic Census, which is done
every five years. The Brookings
report uses these census results
and defines biotechnology as
pharmaceutical and medicine
manufacturing (NAICS 3254) and
life sciences research  and devel-
opment (NAICS 5417102). Based
on the 1997 results, San Antonio
had a small pharmaceutical in-
dustry with 492 jobs but a signif-
icant research and development
presence with 1,124 jobs. Of the
metro areas the study categorizes
as median biotech areas, San
Antonio ranks second, behind the
Denver CMSA, in number of jobs
in life sciences R&D. San Antonio
also had more jobs in this cate-
gory than three of the four metro
areas considered biotech research
centers.
Of the 51 large metro areas
the Brookings study analyzes, San
Antonio ranks 12th in the num-
ber of biotech R&D jobs. But ad-
justing for the size of the metro
area, San Antonio ranks even
higher. Looking at the 16 metro
areas considered biotech centers,
Chart 2






San Francisco–Oakland–San Jose CMSA
San Antonio MSA
Austin–San Marcos MSA
Philadelphia–Wilmington–Atlantic City, PA–NJ–DE–MD CMSA
New York–Northern New Jersey–Long Island, NY–NJ–CT–PA CMSA
Los Angeles–Riverside–Orange County CMSA
Houston–Galveston–Brazoria CMSA
Chicago–Gary–Kenosha, IL–IN–WI CMSA
St. Louis, MO–IL MSA
Dallas–Fort Worth CMSA
Detroit–Ann Arbor–Flint CMSA
0. 2. 4. 6. 811.2 1.4 1.6
Percent
SOURCES: Census Bureau; Bureau of Labor Statistics; Brookings Institution Center on Urban and Metropolitan Policy; authors’ calculations.
NOTE: Data are for 1997.
Vista • Spring 2003 4pirical study done in 1988 found
that the location of “star scientists”
was a significant predictor of
growth in biotechnology firms in
a particular area.
7 The study found
that both star scientists and bio-
tech firms were highly concen-
trated in a small number of
biotech centers and that the rea-
son for this concentration was the
overriding importance of scien-
tific research and intellectual cap-
ital in the growth of this industry. 
Another article reports that
firms with established connec-
tions to stars had an average
increase in employment of 366
workers over 1989–94, versus an
82-employee increase in firms
lacking those ties. Furthermore,
this relationship accounted for
more products in the pipeline
(an average of 10.7) and on the
market (8.8) compared with firms
(1.2 and 3.5, respectively) with-
out proximity to star scientists.
8
The numbers illustrate the im-
portance of top scientists and
academic institutions to the loca-
tion and growth of biotech firms. 
The Brookings report investi-
gates other factors that promote
the growth of biotechnology, such
as the number of life scientists,
Ph.D.’s granted, top-ranked re-
search universities and the area’s
ahead of the other three metro
areas (0.0514 percent), followed
by San Antonio (0.0117), Houston
(0.0081) and Dallas–Fort Worth
(0.0062). Austin is likely the
leader in this category because
of the presence of several large
pharmaceutical companies, includ-
ing Bristol-Myers Squibb Corp.,
Abbott Laboratories and Novartis
Pharmaceuticals Corp.
4
While employment and patent
data show that San Antonio has
generally been successful in 
attracting biotech jobs, particu-
larly in research and develop-
ment, future growth will depend
on whether the city has the char-
acteristics that are attractive to
the industry. One author, writing
on  the prospects for biotech in
Texas, states, “The lifeblood of
biotech companies is knowledge,
labor and capital capable of
enduring the time-consuming,




Biotech start-ups are very dif-
ferent from pharmaceutical man-
ufacturing companies. Biotech-
nology firms focus primarily on
research and development, while
pharmaceuticals concentrate on
manufacturing and marketing new
products. Biotech start-ups aver-
age 14 employees in laboratory/
research services and approxi-
mately 68 employees in the med-
ical-device area.
6 Pharmaceutical
firms employ 138 people on
average.
It is rare for a biotech start-
up to evolve into a large phar-
maceutical firm. Instead, biotech
firms tend to sell or license their
technologies to larger pharma-
ceutical firms, form joint ven-
tures with them or sell them their
entire company. The advantage
of being small is that biotech
firms are more flexible and can
expand much faster than big
pharmaceuticals. However, bio-
tech’s characteristics cause more
volatility, as the success of a
company often rides on the com-
mercialization of only a few
drugs. Marketing a new product
not only takes time—about 15
years, on average—but also mil-
lions of dollars. 
Biotech companies are fueled
by proximity to academic institu-
tions such as universities, indi-
vidual scientists and related-
science tech schools that conduct
basic research. Start-up com-
panies benefit from both ag-
glomeration economies of scale
and knowledge spillovers. An em-
Table 2
Human Capital Measures in Biotech
Change in
Life Top-ranked NIH funding to NIH medical
scientists, Biology Ph.D.’s research top 100 cities, school funding,
Metro areas 1998 granted, 1999 universities, 1982 2000 share 1985–2000
Top three biotech centers
Boston 4,980 355 3 12.2% –1.3%
New York 4,790 519 3 11.8% –3.0%
San Francisco 3,090 215 3 6.0% –1.2%
Texas biotech
Houston 750 135 — 3.6% .5%
Austin 610 58 — .2% .10%
Dallas–Fort Worth 560 77 — 1.1% .0
San Antonio 320 20 — 1.1% –.2%
SOURCE: Brookings Institution Center on Urban and Metropolitan Policy, Signs of Life: The Growth of Biotechnology Centers in the U.S., 2002.
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shows these factors for the bio-
tech areas in Texas and for the
top three biotech centers nation-
ally. As of 1998, 320 life scientists
resided in San Antonio, below
the 426.6 average for the median
metro areas. With only one insti-
tution granting Ph.D.’s in biolog-
ical science in 1999 and 20 Ph.D.’s
awarded that year, San Antonio
is also below the 45 Ph.D. aver-
age. None of the nation’s top 20
medical schools are located in
Texas, while the Boston, San
Francisco and New York metro
areas each have three.
9
All nine of the biotech cen-
ters have at least one top-ranked
medical school, and only four
top-ranked schools are located
someplace other than one of the
nine centers. Nonetheless, San
Antonio receives an above-aver-
age share of NIH funding. The
Brookings report analyzes the
total funding distributed to the
top 100 recipient metro areas
and looks at the share of this
funding received by each of the
51 largest metro areas.  While the
average share of funding was
0.87 percent for the median bio-
tech metropolitan areas, San An-
tonio received 1.1 percent ($123.4
million) in 2000, about the same
as the much larger Dallas–Fort
Worth CMSA, which received
$130.6 million, and more than the
Austin MSA, which got $28 mil-
lion (0.2 percent). NIH funding is
primarily for research at medical
schools and flows disproportion-
ately to areas with well-estab-
lished research facilities. 
A highly skilled workforce is
also essential to biotech growth.
According to Census Bureau esti-
mates on educational attainment,
San Antonio performs rather
poorly in comparison with Dallas,
Austin, Texas and the nation as a
whole.
10 Of the population 25
years and older nationally, 80.4
percent have at least a high
school diploma and 24.4 percent
have at least a bachelor’s degree.
In San Antonio, 77.3 percent are
high school graduates or higher,
and the figure most relevant to
the biotechnology sector—the
percentage of the population with
a bachelor’s degree or higher—
is 22.4 percent. Looking at the
leading biotech centers, the per-
centage with at least a high
school diploma is 85.7 percent in
Boston, 83.9 percent in San
Francisco and 79.4 percent in
New York. The percentage of the
adult population with a bache-
lor’s degree or higher is 34.4 per-
cent in Boston, 37.3 percent in
San Francisco and 30.5 percent
in New York. 
While San Antonio faces tough
challenges in education, the city
is addressing some of these issues.
City officials are working with the
University of Texas at San Antonio
(UTSA) and the University of Texas
Health Science Center to strengthen
San Antonio’s attributes as a bio-
technology center. UTSA is offer-
ing a Ph.D. program in biology
with an emphasis in neurobiology.
Starting this fall, UTSA and the
Health Science Center will offer
a joint Ph.D. program in biomed-
ical engineering. UTSA is sched-
uled to complete a biotechnol-
ogy, science and engineering
building in 2004. The facility will
have 71,000 square feet for re-
search and instructional labs. Also,
in August 2002 renovations and
construction began on the Center
for Excellence in Bioprocessing
and Biotechnology at Brooks City-
Base, where military personnel
and civilians will be taught how
to handle vaccines, biosensors and
other biological products. 
While human capital is im-
portant to biotech growth, a firm’s
early-stage financial capital is also
key. Establishing a functional fac-
ility and buying equipment con-
stitute a substantial part of a firm’s
start-up costs. Biotech companies
flounder without early access to
government funding for basic 
research, such as NIH grants,
“angel” networks (small invest-
San Antonio’s share 
of biotech venture 
capital was small, 
but it was larger 
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capital.
Although capital is critical
during start-up, it’s important at
all stages, especially maturity. The
Brookings report notes that al-
though 51 of the largest metro-
politan areas have demonstrated
an ability to sustain biotech firms,
significant growth requires finan-
cial and commercial backing.
Five of the top nine metro bio-
tech areas—two leaders (Boston
and San Francisco) and three
other areas where biotech is
growing rapidly (San Diego,
Seattle and Raleigh–Durham)—
account for much of the growth
of new biotechnology firms. To-
gether these five areas accounted
for 56 percent of the biotech
businesses formed during the
1990s and 75 percent of the new
venture capital in biopharma-
ceuticals in the past six years. 
The metro areas classified as
biotechnology centers received
billions of dollars in venture
capital over 1995–2001. San Fran-
cisco received $3 billion, 31.1
percent of biotech venture capi-
tal nationwide; Boston got $1.9
billion, 19.7 percent; and San Diego
got $1.5 billion, 15.4 percent.
The median metropolitan areas’
shares of venture capital were
significantly lower, with all but
Denver having slightly less than
1 percent. San Antonio’s share
was small, but it was larger than
that of other Texas metros and
significant given the area’s size.
At 0.9 percent, San Antonio’s
share of U.S. biotech venture cap-
ital was larger than Houston’s
(0.7 percent), Austin–San Marcos’
(0.6 percent) and Dallas–Fort
Worth’s (0 percent). San Antonio
received $90.4 million; Houston,
$72.6 million; and Austin–San
Marcos, $58.4 million.
In a business in which the
ability to innovate determines suc-
cess, young biotech firms find it
advantageous to link up with
other firms—either horizontally
or vertically—to access the fund-
ing necessary to promote inno-
vation and tap the marketing
capabilities a research environ-
ment often lacks. Big pharma-
ceuticals and biotech firms forged
R&D agreements worth $17.3
billion over 1980–2001, accord-
ing to the Brookings report.
Typically, the pharmaceutical firm
buys the rights to or the use of
specific new technologies or pur-
chases marketing privileges for
products nearing commercializa-
tion stages. Biotech firms, in turn,
receive money to continue fur-
ther R&D. From 1990 to 2002, al-
liances with pharmaceutical firms
were highly concentrated in four
large biotech centers that attracted
over 80 percent of the value of
these contracts: Boston, New
York, San Francisco and San
Diego. Houston received about
$108 million and Austin $50 mil-
lion. The Brookings study did
not report any for San Antonio.  
Conclusion
The U.S. biotechnology in-
dustry is highly concentrated in
a handful of large cities that
have well-established and world-
renowned medical institutions and
scientists. A recent Brookings In-
stitution study found that nine
metropolitan areas account for
three-fourths of the nation’s larg-
est biotech firms and three-fourths
of the biotech firms formed in
the past decade. While San An-
tonio is not a large biotech cen-
ter, the industry appears to be
prospering there. The Brookings
report classifies San Antonio as a
median metropolitan area in
terms of its share of the nation’s
biotech industry.
San Antonio’s share of bio-
tech employment is second in
Texas, slightly behind Austin’s.
By several measures, San Antonio
has a significant amount of bio-
tech research and development,
and its pharmaceutical industry,
while not as large as other areas,
grew strongly from 1997 to 2000.
After adjusting for size, San An-
tonio leads the Texas biotech
metros in biotech patents classi-
fied by inventor residence. Meas-
ures of venture capital and NIH
funding going to biotech in San
Antonio are also relatively strong.
San Antonio faces several
challenges. Relatively few Ph.D.’s
are awarded in biological sci-
ences, educational attainment is
low, and the area lacks a nation-
ally recognized top 20 medical
school that would help attract the
star scientists critical to industry
growth. City officials, however,
have recognized the importance
of education to biotech and have
begun several new initiatives with
institutions such as the Univer-
sity of Texas at San Antonio and
the University of Texas Health
Science Center.
— Keith Phillips 
Maria Ritka Dzula
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Structural Change or Cyclical Factors?
Mexico’s maquiladora industry saw its biggest decline ever over the past
two years, and many analysts are questioning the industry’s future. Are
structural changes or cyclical factors the cause of this weakness? Is the
maquiladora industry ready to face rising global competition, or is it the
beginning of a long-term decline? This conference will offer answers to
these questions and more.
November 21, 2003
Sheraton Hotel
South Padre Island, Texas
Hosted by the El Paso and San Antonio Branches
Federal Reserve Bank of Dallas